Список литературы

1. Isidori A. et al. Iron toxicity - Its effect on the bone marrow. // Blood Rev. England, 2018. Vol. 32, N 6. P. 473 - 479.

2. Marsh J.C.W., Kulasekararaj A.G. Management of the refractory aplastic anemia patient: what are the options? // Blood. 2013. Vol. 122, N 22. P. 3561 - 3567.

3. Frickhofen N. et al. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia // Blood. 2003. Vol. 101, N 4. P. 1236 - 1242.

4. Kulasekararaj A.G. et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome // Blood. 2014. Vol. 124, N 17. P. 2698 - 2704.

5. Afable M.G., Tiu R.V., Maciejewski J.P. Clonal Evolution in Aplastic Anemia // Hematology. 2011. N 1. P. 90 - 95.

6. Pu J.J. et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia // Eur. J. Haematol. 2011. Vol. 87, N 1. P. 37 - 45.

7. Socie G. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors // Lancet. 1996. Vol. 348, N 9027. P. 573 - 577.

8. Kulagin A. et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: Results of two-centre prospective study // Br. J. Haematol. 2014. Vol. 164, N 4. P. 546 - 554.

9. Li Y. et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience // Ann. Hematol. 2011. Vol. 90, N 5. P. 529 - 537.

10. Кулагин А.Д. et al. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20 - 28.

11. Kaufman D.W. et al. Relative incidence of agranulocytosis and aplastic anemia // Am. J. Hematol. 2006.

12. Killick S.B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. // Br. J. Haematol. England, 2016. Vol. 172, N 2. P. 187 - 207.

13. Dokal I. Dyskeratosis congenita. // Hematology. 2011. Vol. 2011. P. 480 - 486.

14. Soulier J. Fanconi anemia. // Hematology Am. Soc. Hematol. Educ. Program. 2011. Vol. 2011. P. 492 - 497.

15. Marsh J.C.W. et al. Guidelines for the diagnosis and management of aplastic anaemia // Br. J. Haematol. 2009. Vol. 147, N 1. P. 43 - 70.

16. Михайлова Е.А., Савченко В.Г. Протокол программного лечения больных апластической анемией: комбинированная иммуносупрессивная терапия // Программное лечение заболеваний системы крови / ed. В.Г. Савченко. Москва: Практика, 2012. P. 135 - 150.

17. Peslak S.A., Olson T., Babushok D.V. Diagnosis and Treatment of Aplastic Anemia // Current Treatment Options in Oncology. Springer New York LLC, 2017. Vol. 18, N 12.

18. Nielsen P. et al. Iron Stores in Patients with Myelodysplasia and Aplastic Anemia. // Blood. 2006. Vol. 108, N 11. P. 3726 - 3726.

19. Детская гематология. Клинические рекомендации / ed. Румянцев А.Г., Масчан А.А., Жуковская Е.В. М.: ГЭОТАР-Медиа, 2015. 656 p.

20. Zar H.J., Andronikou S., Nicol M.P. Advances in the diagnosis of pneumonia in children // BMJ. British Medical Journal Publishing Group, 2017. Vol. 358.

21. Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. // Hematology. 2007. P. 29 - 39.

22. de Latour R.P., Risitano A.M., Dufour C. Severe Aplastic Anemia and PNH // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 579 - 587.

23. Barone A. et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP) // Blood Cells, Mol. Dis. Elsevier B.V., 2015. Vol. 55, N 1. P. 40 - 47.

24. Frisch B., Lewis S.M. The bone marrow in aplastic anaemia: diagnostic and prognostic features // J. Clin. Pathol. 1974. Vol. 27, N 3. P. 231 - 241.

25. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies // Blood. 2008. Vol. 112, N 4. P. 965 - 974.

26. Maciejewski J.P. et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia // Blood. 2002. Vol. 99, N 9. P. 3129 - 3135.

27. Gupta V. et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults // Br. J. Haematol. 2006. Vol. 134, N 1. P. 95 - 99.

28. Михайлова Е.А. et al. Комбинированная иммуносупрессивная терапия больных апластической анемией: повторные курсы антитимоцитарного глобулина // ГЕМАТОЛОГИЯ И ТРАНСФУЗИОЛОГИЯ. 2014. Vol. 59, N 4. P. 11 - 18.

29. Young N.S., Bacigalupo A., Marsh J.C.W. Aplastic Anemia: Pathophysiology and Treatment // Biol. Blood Marrow Transplant. 2010. Vol. 16, N 1. P. S119 - S125.

30. Bacigalupo A. How I treat acquired aplastic anemia // Blood. 2017. Vol. 129, N 11. P. 1428 - 1436.

31. Scheinberg P., Young N.S. How I treat acquired aplastic anemia. // Blood. 2012. Vol. 120, N 6. P. 1185 - 1196.

32. Desmond R. et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug // Blood. 2014. Vol. 123, N 12. P. 1818 - 1825.

33. Kelsey P. et al. Guidelines for the use of platelet transfusions // Br. J. Haematol. 2003. Vol. 122, N 1. P. 10 - 23.

34. Hartung H.D., Olson T.S., Bessler M. Acquired Aplastic Anemia in Children // Pediatr. Clin. North Am. NIH Public Access, 2013. Vol. 60, N 6. P. 1311.

35. Bacigalupo A. et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: Survival advantage for bone marrow in all age groups // Haematologica. Haematologica, 2012. Vol. 97, N 8. P. 1142 - 1148.

36. Scheinberg P. et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia // N. Engl. J. Med. 2011. Vol. 365, N 5. P. 430 - 438.

37. Chen M. et al. Posaconazole as primary prevention of fungal infection in intensive immunosuppressive therapy for severe aplastic anemia // Zhonghua Xue Ye Xue Za Zhi. 2018. Vol. 39, N 2. P. 128 - 131.

38. Valdez J.M. et al. Infections in patients with aplastic anemia // Semin. Hematol. Semin Hematol, 2009. Vol. 46, N 3. P. 269 - 276.

39. Lee J.W. et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial // Blood. 2010. Vol. 116, N 14. P. 2448 - 2454.

40. Hong Y. et al. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis. // Clin. Drug Investig. 2019. Vol. 39, N 2. P. 141 - 156.

41. Filippidou M. et al. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia // Br. J. Haematol. John Wiley & Sons, Ltd, 2020. Vol. 190, N 3. P. e157 - e159.

42. Богачева Н.Ю., Шнейдер М.М., Масчан А.А. "Циклоспориновая зависимость" при лечении тяжелой апластической анемии у детей // Гематология и трансфузиология. 1996. Vol. 41, N 2. P. 18 - 21.

43. Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies / ed. Carreras E. et al. Springer, 2019. P. 87 - 99.

44. Carreras E., Rambaldi A. Evaluation and Counseling of Candidates // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 77 - 87.

45. Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries // Thomas' Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 1 - 2. P. 423 - 432.

46. Witt V., Peters C. Collection of HSC in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 123 - 127.

47. Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109 - 117.

48. Hubel K. Mobilization and Collection of HSC // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 117 - 123.

49. Querol S., Rocha V. Procurement and Management of Cord Blood // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 131 - 137.

50. Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 127 - 131.

51. Schumm M., Lang P., Handgretinger R. Graft Manipulation // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 137 - 143.

52. Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99 - 109.

53. Danylesko I., Shimoni A., Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike // Bone Marrow Transplant. 2012 471. Nature Publishing Group, 2011. Vol. 47, N 1. P. 5 - 14.

54. Ruutu T. How to use busulfan in conditioning for allogeneic transplantation // Cell. Ther. Transplant. Universitatsklinikum Hamburg - Eppendorf, 2018. Vol. 7, N 1. P. 18 - 20.

55. Langenhorst J.B. et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation // Clin. Pharmacokinet. Springer, 2019. Vol. 58, N 5. P. 627.

56. Yoshida N. et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide // Bone Marrow Transplant. 2020 557. Nature Publishing Group, 2020. Vol. 55, N 7. P. 1272 - 1281.

57. Penack O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, N 2. P. e157 - e167.

58. Michonneau D., Socie G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177 - 183.

59. Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children // Bone Marrow Transplant. 2010 457. Nature Publishing Group, 2009. Vol. 45, N 7. P. 1161 - 1166.

60. Jacoby E. et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies // Biol. Blood Marrow Transplant. NIH Public Access, 2016. Vol. 22, N 1. P. 112.

61. Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, N 2. P. 224.

62. Koreth J. et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 3. P. 522 - 530.

63. Wertheimer T. et al. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis // Ann. Hematol. 2021. Vol. 100, N 3. P. 779 - 787.

64. Drobyski W.R. et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Elsevier, 2011. Vol. 17, N 12. P. 1862 - 1868.

65. Abouelnasr A. et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment // Biol. Blood Marrow Transplant. 2013. Vol. 19. P. 12 - 21.

66. Schafer H. et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT // Ann. Hematol. 2021 1008. Springer, 2021. Vol. 100, N 8. P. 2095 - 2103.

67. Malard F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study // Blood. Content Repository Only!, 2017. Vol. 130, N 20. P. 2186 - 2195.

68. Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease // Thomas' Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 2 - 2. P. 1012 - 1025.

69. Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 136, N 4. P. 429 - 440.

70. Martin P.J. How I treat steroid-refractory acute graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 135, N 19. P. 1630 - 1638.

71. Nassar A. et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation // J. Transplant. Hindawi Limited, 2014. Vol. 2014. P. 1 - 10.

72. Kawashima N. et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan // Int. J. Hematol. 2019 1094. Springer, 2019. Vol. 109, N 4. P. 491 - 498.

73. Khandelwal P. et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients // Pediatr. Transplant. Pediatr Transplant, 2014. Vol. 18, N 1. P. 94 - 102.

74. Vicent M.G. et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results // Am. J. Hematol. John Wiley & Sons, Ltd, 2019. Vol. 94, N 3. P. 319 - 326.

75. Faraci M. et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients // Biol. Blood Marrow Transplant. Elsevier, 2019. Vol. 25, N 4. P. 743 - 748.

76. Sleight B.S. et al. Infliximab for GVHD therapy in children // Bone Marrow Transplant. 2007 405. Nature Publishing Group, 2007. Vol. 40, N 5. P. 473 - 480.

77. Albert M.H. et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment // Pediatr. Transplant. Pediatr Transplant, 2007. Vol. 11, N 3. P. 306 - 309.

78. Zangrilli A. et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus // Pediatr. Int. Pediatr Int, 2010. Vol. 52, N 3. P. e161 - 3.

79. Baird K. et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2015. Vol. 21, N 6. P. 1083 - 1090.

80. Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 331 - 347.

81. Filipovich A.H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2005. Vol. 11, N 12. P. 945 - 956.

82. Jagasia M.H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, N 3. P. 389 - 401. e1.

83. Mikulska M. Infection Control and Isolation Procedures // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 189 - 197.

84. Mikulska M. Neutropenic Fever // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 259 - 265.

85. Ljungman P., Styczynski J., Einsele H. Viral Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 281 - 291.

86. Maertens J.A. Invasive Fungal Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 273 - 281.

87. Groll A.H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, N 8.

88. Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 387 - 393.

89. Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 315 - 323.

90. Mahadeo K.M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, N 1. P. e61 - e72.

91. Sung L. et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation // BMJ Supportive and Palliative Care. BMJ Publishing Group, 2017. Vol. 7, N 1. P. 7 - 16.

92. Ghali M.G.Z. et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management // Leukemia and Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, N 10. P. 2365 - 2372.

93. Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again // Pediatr. Transplant. John Wiley & Sons, Ltd, 2005. Vol. 9, N SUPPL. 7. P. 25 - 36.

94. Jodele S. et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy // Transfusion and Apheresis Science. Elsevier Ltd, 2016. Vol. 54, N 2. P. 181 - 190.

95. Baumgartner A., Schuetz P. Nutritional Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 171 - 177.

96. Schrezenmeier H. et al. Transfusion Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 163 - 171.

97. Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future // Archives of Pathology and Laboratory Medicine. College of American Pathologists, 2018. Vol. 142, N 5. P. 662 - 667.

98. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.